These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2868592)

  • 21. Stable L-forms of Clostridium perfringens: growth, toxin production, and pathogenicity.
    Mahony DE
    Infect Immun; 1977 Jan; 15(1):19-25. PubMed ID: 188763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamics of plc gene transcription and alpha-toxin production during growth of Clostridium perfringens strains with contrasting alpha-toxin production.
    Abildgaard L; Schramm A; Rudi K; Højberg O
    Vet Microbiol; 2009 Oct; 139(1-2):202-6. PubMed ID: 19559545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new growth and in vitro sporulation medium for Clostridium perfringens.
    Meyer M; Tholozan JL
    Lett Appl Microbiol; 1999 Feb; 28(2):98-102. PubMed ID: 10063637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of Clostridium perfringens selective chromogenic medium].
    Wang J; Chen P; Li Q; Ren C
    Wei Sheng Yan Jiu; 2013 Jul; 42(4):656-9. PubMed ID: 24024383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Approbation of nutrient media made of dry components for the accelerated cultivation of Cl. perfringens type A].
    Kurbanova IZ; Zemlianitskaia EP; Ertuganova ZA; Sergeeva TI; Stal'makova VP
    Zh Mikrobiol Epidemiol Immunobiol; 1979 Jul; (7):115. PubMed ID: 224626
    [No Abstract]   [Full Text] [Related]  

  • 26. [Method of determining the biochemical behavior of clostridia].
    Petkov A; Lulov R
    Vet Med Nauki; 1981; 18(9):37-42. PubMed ID: 6283724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An activity which restores theta toxin activity in some theta toxin-deficient mutants of Clostridium perfringens.
    Imagawa T; Higashi Y
    Microbiol Immunol; 1992; 36(5):523-7. PubMed ID: 1513265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Removal of proteases from Clostridium perfringens fermented broth by aqueous two-phase systems (PEG/citrate).
    Porto TS; Pessôa-Filho PA; Neto BB; Filho JL; Converti A; Porto AL; Pessoa A
    J Ind Microbiol Biotechnol; 2007 Aug; 34(8):547-52. PubMed ID: 17566805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A method for preparing a pre-reduced, chemically defined, filter sterilized medium for growing Clostridium perfringens.
    Ades GL; Pierson MD
    J Appl Bacteriol; 1973 Dec; 36(4):739-41. PubMed ID: 4362617
    [No Abstract]   [Full Text] [Related]  

  • 30. Production of toxic enzymes of Clostridium perfringens BP6K on technologically important media including a medium with Tween 80.
    Lettl A
    J Hyg Epidemiol Microbiol Immunol; 1978; 22(2):243-8. PubMed ID: 217931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Production, purification and characterization of some Clostridium perfringens toxins].
    Capunzo M; Mariano A; Cavallo R
    G Batteriol Virol Immunol; 1982; 75(1-6):48-61. PubMed ID: 6315516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced production of phospholipase C and perfringolysin O (alpha and theta toxins) in a gatifloxacin-resistant strain of Clostridium perfringens.
    Rafii F; Park M; Bryant AE; Johnson SJ; Wagner RD
    Antimicrob Agents Chemother; 2008 Mar; 52(3):895-900. PubMed ID: 18160514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved culture techniques and sporulation medium for enterotoxin production by Clostridium perfringens type A.
    Tsai CC; Torres-Anjel MJ; Riemann HP
    Taiwan Yi Xue Hui Za Zhi; 1974 Jul; 73(7):404-9. PubMed ID: 4373517
    [No Abstract]   [Full Text] [Related]  

  • 34. Ethanolamine utilization supports Clostridium perfringens growth in infected tissues.
    Yagi H; Nakayama-Imaohji H; Nariya H; Tada A; Yamasaki H; Ugai H; Elahi M; Ono T; Kuwahara T
    Microb Pathog; 2018 Jun; 119():200-207. PubMed ID: 29654901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Patterns in the development of deep cultures of Cl. perfringens].
    Akhundova KA; Nenashev VP; Artemenko VD
    Zh Mikrobiol Epidemiol Immunobiol; 1970 Dec; 47(12):29-34. PubMed ID: 4324430
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of a new, bismuth-iron-sulfite-cycloserine agar for isolation of Clostridium perfringens with the tryptose-sulfite-cycloserine and blood agars.
    Gubash SM; Ingham L
    Zentralbl Bakteriol; 1997 Feb; 285(3):397-402. PubMed ID: 9084113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Purification of alpha toxin from Clostridium perfringens: phospholipase C.
    Jolivet-Reynaud C; Moreau H; Alouf JE
    Methods Enzymol; 1988; 165():91-4. PubMed ID: 2906730
    [No Abstract]   [Full Text] [Related]  

  • 38. Chemically defined medium for the growth of Clostridium perfringens.
    Riha WE; Solberg M
    Appl Microbiol; 1971 Oct; 22(4):738-9. PubMed ID: 4331776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a minimal medium for Clostridium perfringens by using an anaerobic chemostat.
    Goldner SB; Solberg M; Post LS
    Appl Environ Microbiol; 1985 Aug; 50(2):202-6. PubMed ID: 2864896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The enteric toxins of Clostridium perfringens.
    Smedley JG; Fisher DJ; Sayeed S; Chakrabarti G; McClane BA
    Rev Physiol Biochem Pharmacol; 2004; 152():183-204. PubMed ID: 15517462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.